Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression

Behavioural Brain Research

Volumn 224, Issue 1, 2011, Pages 107-111

  Koike, Hiroyuki ^a   Iijima, Michihiko ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

AMPA receptor; Antidepressant; Ketamine; Learned helplessness paradigm; Tail suspension test

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; DESIPRAMINE; KETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; LEARNED HELPLESSNESS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; EXCITATORY AMINO ACID ANTAGONISTS; HELPLESSNESS, LEARNED; HINDLIMB SUSPENSION; KETAMINE; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; TIME FACTORS;

EID: 79959350106     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.05.035     Document Type: Article

References (36)

1. Auer D.P., Pütz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000, 47:305-313.
2. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra- and interstrain differences in models of "behavioral despair" Pharmacol Biochem Behav 2001, 70:187-192.
3. Bechtholt-Gompf A.J., Smith K.L., John C.S., Kang H.H., Carlezon W.A., Cohen B.M., et al. CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) 2011, 215:689-695.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
5. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry, in press.
6. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
7. DiazGranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010, 71:1605-1611.
8. Dravid S.M., Erreger K., Yuan H., Nicholson K., Le P., Lyuboslavsky P., et al. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol 2007, 581:107-128.
9. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:140-144.
10. Karasawa J., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005, 1042:92-98.
11. Klepstad P., Maurset A., Moberg E.R., Oye I. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 1990, 187:513-518.
12. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
13. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
14. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
15. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007, 9:467-474.
16. Maxwell C.R., Ehrlichman R.S., Liang Y., Trief D., Kanes S.J., Karp J., et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther 2006, 316:315-324.
17. Mirza Y., Tang J., Russell A., Banerjee S.P., Bhandari R., Ivey J., et al. Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 2004, 43:341-348.
18. O'Neill M.J., Witkin J.M. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007, 8:603-620.
19. Pałucha-Poniewiera A., Wierońska J.M., Brański P., Stachowicz K., Chaki S., Pilc A. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) 2010, 212:523-535.
20. Pilc A., Chaki S., Nowak G., Witkin J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008, 75:997-1006.
21. Pittenger C., Sanacora G., Krystal J.H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007, 6:101-115.
22. Popik P., Kos T., Sowa-Kućma M., Nowak G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 2008, 198:421-430.
23. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
24. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
25. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
26. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66:522-526.
27. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004, 43:1146-1153.
28. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
29. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
30. Sherman A.D., Sacquitne J.L., Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982, 16:449-454.
31. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
32. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005, 4:131-144.
33. Tigaret C.M., Thalhammer A., Rast G.F., Specht C.G., Auberson Y.P., Stewart M.G., et al. Subunit dependencies of N-methyl-d-aspartate (NMDA) receptor-induced alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor internalization. Mol Pharmacol 2006, 69:1251-1259.
34. Venable N., Kelly P.H. Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology (Berl) 1990, 100:215-221.
35. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002, 71:341-344.
36. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.